CURRICULUM VITAE Personal Details Surname: Kuloglu First Name: Murat Akademic title/ position: Professor Key Qualifications: Schizophrenia, Biological Psychiatry Research Interest: Psychopharmacology International Experience/Collaborations: Contact Details: Work Address: Name of Hospital: Town: Country: Fırat University Medical Faculty, Psychiatry Department Elazıg Turkey Post Code: 23100 Phone/Fax: 2333555 Email: kuloglum@yahoo.com Date of Birth: 1966 Place and Country of Birth: Country of Citizenship: Country of Training: First Language: Languages: Elazıg/Turkey Turkish Republic Turkey Turkish English
Akademic Details Faculty/University ( name and address) Fırat University Medical Faculty/Elazıg Date of Graduation: 1989 Postgraduate Training: Ataturk University Medical Faculty, Psychiatry Department SUPERVISOR IN CHARGE OF TRAINING: From 1991 To 1995 Title of thesis: The efficacy of bromocriptine, a dopamine agonist, in the treatment of negative symptoms in schizophrenic patients Academic Experience: Resident Dr. : Specialist Dr. : Assist. Assoc. Prof.: Assoc. Prof. : Assoc. Prof. : Ataturk University Medical Faculty, Psychiatry Department 1991-1995 Elazıg Mental Health and Đlness Hospital 1995-1996 Fırat University Medical Faculty, Psychiatry Department 1996-2003 Fırat University Medical Faculty, Psychiatry Department 2003-2004 Elazıg Training and Research Hospital 2004-2005 Assist. Clinic. Supervisor : Ankara Ataturk Training and Research Hospital 2005-2008 Assoc. Prof. : Fırat University Medical Faculty, Psychiatry Department 2008-Currently Memberships: Turkish Psychiatry Society, Turkish Social Psychiatry Society International Publications
Clinical Trials: 1. Kuloğlu, M., M. Atmaca, A.E. Tezcan, A. Ünal, Ö. Geçici, Color and number preferences of patients with psychiatric disorders in Eastern Turkey, Percept Mot Skills, 94, 207-13 (2002). 2. Kuloğlu, M., M. Atmaca, A.E. Tezcan, Ö. Geçici, H. Tunçkol, B. Üstündağ, Antioxidant enzyme activities and malondialdehyde levels in patients with obsessive compulsive disorder, Neuropsychobiology, 46, 27-32 (2002). 3. Kuloğlu, M., M. Atmaca, A.E. Tezcan, B. Üstündağ, S. Bulut, Antioxidant enzyme and malondialdehyde levels in patients with panic disorder, Neuropyschobiology, 46, 186-9 (2002). 4. Atmaca, M., M. Kuloğlu, A.E. Tezcan, B. Üstündağ, Ö Gecici, B. Firidin, Serum leptin and cholesterol values in the suicide attempters, Neuropsychobiology, 45, 124-7 (2002). 5. Atmaca, M., M. Kuloğlu, A.E. Tezcan, B. Üstündağ, Serum cholesterol and leptin values in patients with borderline personality disorder, Neuropsychobiology, 45, 167-71 (2002). 6. Atmaca, M., M. Kuloğlu, A.E. Tezcan, B. Üstündağ, Weight gain and serum leptin levels in patients on lithium treatment, Neuropsychobiology, 46, 67-9 (2002). 7. Kuloğlu, M., B. Üstündağ, M. Atmaca, H. Canatan, A.E. Tezcan, N. Çinkılınc, Lipid peroxidation and antioxidant enzyme levels of patients with schizophrenia and bipolar disorder, Cell Biochem Funct, 20, 171-5 (2002). 8. Kavuncu, V., M. Kuloğlu, A. Kaya, S. Şahin, M. Atmaca, B. Firidin, Bone metabolism and bone mineral density in premenapausal women with mild depression, Yonsei Med J, 43, 101-8 (2002). 9. Atmaca, M., M. Kuloğlu, A.E. Tezcan, A. Semerciöz, B Üstündağ, A. Ayar, Serum leptine levels in patients with premature ejeculation, Arch Andrology,48, 345-50, 2002. 10. Atmaca, M., M. Kuloğlu, A.E. Tezcan, S. Önal, B. Üstündağ, Neopterin levels and dexamethasone supression test in posttraumatic stress disorder, Eur Arch Psychiatry Clin Neurosci, 252, 161-5 (2002). 11. Atmaca, M., M. Kuloğlu, A.E. Tezcan, Sildenafil use in patients with olanzapineinduced erectile dysfunction, Int. J. Impotance Res, 14, 547-9 (2002). 12. Atmaca, M., M. Kuloğlu, A.E. Tezcan, A. Semerciöz, The efficacy of citalopram in the treatment of premature ejaculation: a placebo controlled study, Int. J. Impotance Res, 14, 502-5 (2002). 13. Atmaca, M., M. Kuloğlu, A.E. Tezcan, A. Ünal, Efficacy of citalopram and moclobemide in patients with social phobia: some preliminary findings, Hum. Psychopharmacol. Clin. Exp, 17, 401-5 (2002).
14. Atmaca, M., M. Kuloğlu, A.E. Tezcan, B. Üstündağ, Serum leptin and cholesterol levels in the patients with bipolar disorder, Neuropyschobiology, 46, 176-9 (2002). 15. Atmaca, M., M. Kuloğlu, A.E. Tezcan, Ö. Geçici, H. Canatan, Quetiapine is not associated with increase in prolactin secretion in contrast to haloperidolin patients with schizophrenia, Arch. Med. Res, 33, 562-5 (2002). 16. Atmaca, M., M. Kuloğlu, A.E. Tezcan, Ö Gecici, Quetiapine augmentation in patients with treatment resistant obsessive-compulsive disorder: a single-blind, placebo- controlled study, Int. Clin. Psychopharmacol, 17, 115-9 (2002). 17. Kuloğlu, M., M. Atmaca, B. Üstündağ, H. Canatan, Ö. Geçici, A.E. Tezcan, Serum iron levels in schizophrenic patients with or without akathisia, Eur. Neuropsychopharmacol, 13, 67-71(2003). 18. Kuloğlu, M., M. Atmaca, A.E. Tezcan, Ö. Geçici, S. Bulut, Sociodemographic and clinical characteristics of patients with conversion disorder in Eastern Turkey, Soc Psychiatr. Psychiatric Epidemiol, 38, 88-93 (2003). 19. Atmaca, M., M. Kuloğlu, A.E. Tezcan, A. Semerciöz, B. Üstündağ, Serum leptin levels in patients with premature ejaculation before and after citalopram treatment, BJU Int, 91, 252-4 (2003). 20. Atmaca, M., M. Kuloğlu, A.E. Tezcan, A. Büyükbayram, Switching to tianeptine in patients with antidepressant-induced sexual dysfunction, Hum Psychopharmacol Clin Exp, 18, 277-80 (2003). 21. Atmaca, M., A.E. Tezcan, M. Kuloğlu, S. Önal, Neopterin production in posttraumatic stress disorder before and after pharmachotherapy, Eur. Arch. Psychiatry Clin. Neurosci, 253, 34-6 (2003). 22. Tezcan, A.E., M. Atmaca, M. Kuloğlu, B. Üstündağ, Free radicals in patients with posttraumatic stress disorder, Eur. Arch. Psychiatry Clin. Neurosci, 253, 89-91 (2003). 23. Tezcan, A.E., M. Atmaca, M. Kuloğlu, Ö. Geçici, A. Büyükbayram, H. Tutkun, Dissociative disorders in Turkish inpatients with conversion disorder, Comp. Psychiatry, 44, 324-30 (2003). 24. Atmaca, M., M. Kuloğlu, A.E. Tezcan, B. Üstündağ, Serum leptin and triglyceride levels in patients on antipsychotic treatment with atypical antipsychotics, J. Clin. Psychiatry, 64, 598-604 (2003). 25. Atmaca, M., M. Kuloğlu, A.E. Tezcan, B. Üstündağ, Nizatidine treatment and its relationship with leptin levels in patientts with olanzapine-induced weight gain, Hum. Psychopharmacol. Clin. Exp, 18, 457-61 (2003). 26. Atmaca, M., M. Kuloğlu, A.E. Tezcan, B. Üstündağ, Serum leptin and cholesterol levels in schizophrenic patients with and without suicide attempts. Acta Psychiatr Scand. 108, 208-14 (2003).
27. Atmaca, M., M. Kuloğlu, A.E. Tezcan, B. Üstündağ, N. Kılıç, Nizatidine for the treatment of patients with quetiapine-induced weight gain, Hum Psychopharmacol, 19:37-40 (2004). 28. Atmaca, M., A.E. Tezcan, M. Kuloğlu, B. Üstündağ, H.Tunçkol Antioxidant enzyme and malondialdehyde values in social phobia before and after citalopram treatment, Eur Arch Psychiatry Clin. Neurosci, 254, 231-35 (2004). 29. Atmaca, M., M. Kuloğlu, A.E. Tezcan, A new atypical antipsychotic: quetiapineinduced sexual dysfunctions Int. J. Impotance Res, 1-3 (2004). 30. Atmaca, M., A.E. Tezcan, M. Kuloğlu, B. Üstündağ, Serum leptin levels in obsessivecompulsive disorder, Psychiatry and Clin. Neurosci, 59, 189-1 (2005). 31. Atmaca, M., A.E. Tezcan, M. Kuloğlu, Ö. Kırtaş, B. Üstündağ, Serum folate and homocysteine levels in patients with obsessive-compulsive disorder, Psychiatry and Clin. Neurosci, 59, 616-20 (2005). 32. Atmaca, M., A.E. Tezcan, M. Kuloğlu, B. Üstündağ, Plasma nitrate values in patients with obsessive-compulsive disorder, Psychiatry and Clin. Neurosci, 59, 621-3 (2005). 33. Geçiçi Ö., M. Kuloğlu, M. Atmaca,AE. Tezcan,H. Tunçkol,M. Emül,B. Üstündağ. High serum leptin levels in depressive disorders with atypical features. Psychiatry Clin Neurosci, 59:736-8 (2005). 34. Atmaca M., E. Tezcan, M. Kuloğlu, B. Üstundağ, Ö. Kırtas. The effect of extract of ginkgo biloba addition to olanzapine on therapeutic effect and antioxidant enzyme levels in patients with schizophrenia. Psychiatry Clin Neurosci, 59: 652-6 (2005). 35. Kuloğlu, M., Ö.Geçici, M. Atmaca, A. Kalkan, ĐH. Bahçecioğlu, K.Demirdağ, E. Tezcan, SS.Kılıç Hepatitis B and Hepatitis C virus infection in institutionalized schizophrenia and other psychotic disorders patients in Eastern Turkey Neurology Psychiatry and Brain Research 13:159-64 (2006). 36. Kuloğlu, M., M. Atmaca, S. Önal, Ö. Geçici, V. Bulut, A.E. Tezcan, Neopterin levels and dexamethasone supression test in obsessive-compulsive disorder, Psychiatry Res, 151: 265-70 (2007). 37. Çayköylü A., M. Kuloğlu, Ö.Geçici, Đ. Coşkun, Đ. Kırpınar The effects of antidepressant treatment on serum cholesterol and triglyceride levels in depressive patients Neurology Psychiatry and Brain Research 14:13-8 (2007). 38. Atmaca M., M. Kuloğlu, E. Tezcan, B. Üstündağ Serum leptin and cholesterol values in violent and non-violent suicide attempters Psychiatry Res, 158: 87-91 (2008). 39. Atmaca M., M. Kuloğlu, E. Tezcan, B. Üstündağ Antioxidant enzyme and malondialdehyde levels in patient with social phobia Psychiatry Res, (2008) 159: 95-100 (2008). Case Reports:
40. Atmaca, M., M. Kuloğlu, A. Ünal, A.E. Tezcan, The detergent is circulating in my blood: A case report, Int. J. Psychiatr. Clin. Pract, 6, 117-9 (2002). 41. Atmaca, M., M. Kuloğlu, A.E. Tezcan, Quetiapine-associated and dose related hypomania in a w1man with schizophrenia, European Psychiatry, 17, 1-2 (2002). 42. Kuloğlu, M., A. Çayköylü, E. Yılmaz, O. Ekinci, A left temporal lobe arachnoid cyst in a patient with schizophrenia-like psychosis: A case report Prog Neuropsychopharmacol Biol Psychiatry, 32, 1349-50 (2008). 43. Çayköylü A.,O. Ekinci, M. Kuloğlu, Improvement from treatment resistant schizoaffective disorder, manic type after stopping heavy caffeine intake: A case report Prog Neuropsychopharmacol Biol Psychiatry, 32, 1353-4 (2008). 44. Çayköylü A., O. Ekinci, Y. Albayrak, M. Kuloğlu, O. Deniz, Arnold-Chiari I malformation association with generalized anxiety disorder: A case report Prog Neuropsychopharmacol Biol Psychiatry, 32, 1613-4 (2008). 45. Kuloğlu, M., A. Çayköylü, O. Ekinci, E. Yılmaz, Lamotrigine-induced obsessional symptoms in a patient with bipolar II disorder: A case report J Psychopharmacol, (2008) Baskıda. 46. A. Çayköylü, O. Ekinci, M. Kuloğlu, O. Deniz, Aripiprazole induced rabbit syndrome: A case report J Psychopharmacol, (2008) in press. Letter to the Editor: 47. Millet, B., M. Leclaire, C. Bourdel, H. Loo, A.E. Tezcan, M. Kuloğlu, Comparison of sociodemographic, clinical and phenomenological charasteristics of Turkish and French patients suffering from obsessive-compulsive disorder, Can. J. Psychiatry, 45, 848 (2000). 48. Atmaca, M., M. Kuloğlu, A.E. Tezcan, B. Üstündağ, Ö. Geçici, Weight gain, serum leptin and triglyceride levels in the patients with schizophrenia on antipsychotic treatment with quetiapine, olanzapine and haloperidol, Schizophrenia Res, 60, 99-100 (2003). 49. Atmaca, M., A.E. Tezcan, M. Kuloğlu. An open clinical trial of reboxetine in the treatment of social phobia, J. Clin. Psychopharmacol, 23, 417-9 (2003). 50. Kuloğlu, M., A. Çayköylü, O. Ekinci, D. Bayındırlı, G. Vural, O. Deniz Successful management of depression with reboxetine in a patient who developed parkinsonism related to paroxetine use J Psychopharmacol, (2008) in press. 51. Kuloğlu, M., O. Ekinci, A. Çayköylü, Venlafaxine-associated nocturnal bruxism in a depressive patient succesfully treated with buspirone J Psychopharmacol, (2009) in press. Presentations at International Scientific Meetings
1. Akyol, A., A.E. Tezcan, S. Akarsu, M. Kuloğlu, Epilepsy and conversion disorder among children in Elazığ region, 5th Asian and Ocenian Congress of Child Neurology, p.78, Đstanbul, Turkey, 1996. 2. Kuloğlu, M., M. Ay, M. Namlı, A.E. Tezcan, Đ. Halifeoğlu, C. Hepgüvendik, Serum calcium levels and cognitive disturbance in tardive dyskinesia, 6th World Congress of Biological Psychiatry, Biological Psychiatry Vol. 142 (suppl) p.180s, Nice, France, 1997. 3. Tezcan A.E, M. Atmaca, F. Ülkeroğlu, M. Kuloğlu, C. Karabulut, EEG abnormalities in schizophrenic patients who treated with clozapine 6th World Biological Congress, Biological Psychiatry Vol 142 (suppl) p.44-45s, Nice, France, 1997. 4. Kuloğlu, M., M. Namlı, M. Ay, M. Atmaca, A.E. Tezcan, Plasma lipid levels in patients with panic disorder, An International Symposium on Neurophysiological and Neuropsychological Assessment of Mental and Behavioural Disorders, Program and Abstract Book, p.49, Bursa, Turkey, 1997. 5. Kuloğlu, M., M. Ay, A.E. Tezcan, M. Namlı, C. Hepgüvendik, Comparison of DST, CPK and basal cortisol levels in negative and positive schizophrenic patients, An International Symposium on Neurophysiological and Neuropsychological Assessment of Mental and Behavioural Disorders, Program and Abstract Book, p.50, Bursa, Turkey, 1997. 6. Kuloğlu, M., A.E.Tezcan, M. Atmaca, C. Karabulut, Distribution of psychiatric diagnosis in elderly patients who applied to university hospital, International Psychogeriatric and Turkish Society of Psychogeriatrics. A Joint Meeting, p.41, Đstanbul, Turkey, 1998. 7. Kuloğlu, M., A.E. Tezcan, M. Atmaca, M. Namlı, Ö. Geçici, Psychosocial and environmental problems in elderly period psychiatric disorders, International Psychogeriatric and Turkish Society of Psychogeriatrics. A Joint Meeting, p.98, Đstanbul, Turkey, 1998. 8. Kuloğlu, M., M.Atmaca, Ö.Geçici, A.E. Tezcan, Terror and internal migration in patients diagnosed as PTSD in Elazığ region, 6th European Conferance on Traumatic Stress, p.140, Đstanbul, 1999. 9. Atmaca, M., M. Kuloğlu, E. Tezcan, Ö. Geçici, A, Ünal, B. Firidin. The comparison of quetiapine and haloperidol effects on serum prolactin in patients with schizophrenia, European Neuropsychopharmacology, Vol 11 (suppl 3) p.240s, 2001. 10. Atmaca, M., M. Kuloğlu, E. Tezcan, Ö. Geçici, Y, Bayık, A. Ünal, H. Tunçkol. The comorbidity of obsessive compulsive disorder and bipolar disorder, European Neuropsychopharmacology, Vol 11 (suppl 3) p.293-294s, 2001.